Αρχική World News Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast... World News Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases Από Ogkologos - 28 Νοεμβρίου, 2025 410 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Rucaparib Extends PFS in the Maintenance Treatment of Recurrent EOC Without... 1 Σεπτεμβρίου, 2020 Working to Address Inequities in Cancer Care: 2021 ASCO Annual Meeting... 8 Ιουλίου, 2021 Teenage (…and young adult) kicks 5 Απριλίου, 2023 Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... 9 Νοεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ Singer Rebecca Crews, Wife Of Terry Crews, Diagnosed With Breast Cancer... Reflecting On My Time As the Cancer.Net Editor in Chief Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells